View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Alpine Select AG: 1 director

A director at Alpine Select AG bought 5,385 shares at 7.300CHF and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: June 10, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Macerich Reports First Quarter 2025 Results

Macerich Reports First Quarter 2025 Results SANTA MONICA, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) has released its First Quarter 2025 Earnings Results and Supplemental Information by posting it to the Investor Relations section of its website at . As previously announced, management will hold a conference call at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) today, Monday, May 12, 2025, to discuss quarterly results. Participants who wish to join the conference by telephone must register using the dial-in registration link below to receive the dial-in ...

American Homes 4 Rent: 2 directors

Two Directors at American Homes 4 Rent sold after exercising options/sold 67,500 shares at between 38.891USD and 39.012USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by a...

 PRESS RELEASE

Genelux Corporation Reports First Quarter 2025 Financial Results and P...

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates.   “The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications, with encouraging regulatory feedback from the FDA on our OnPrime Phase ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 3, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Genelux Corporation to Participate in a Fireside Chat at the Citizens ...

Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that , President, CEO and Chairman of the Board, and , CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York. The conversation with Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to begin at 1:30 p.m. ET on Thursd...

 PRESS RELEASE

Macerich Declares the Quarterly Dividend on Its Common Shares

Macerich Declares the Quarterly Dividend on Its Common Shares SANTA MONICA, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of the Macerich Company (NYSE: MAC) declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on June 17, 2025, to stockholders of record at the close of business on June 3, 2025. About MacerichMacerich is a fully integrated, self-managed, self-administered real estate investment trust (REIT). As a leading owner, operator, and developer of high-quality retail real estate in densely populated and attractive U.S....

 PRESS RELEASE

Macerich Schedules First Quarter 2025 Earnings Release and Conference ...

Macerich Schedules First Quarter 2025 Earnings Release and Conference Call SANTA MONICA, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- WHAT: Macerich (NYSE: MAC) Schedules First Quarter 2025 Earnings Release and Conference Call  WHEN: Earnings Results will be released before market open on Monday, May 12, 2025. Management will hold a conference call at 10:00 am Pacific Time (1:00 pm Eastern Time) on that same day to discuss quarterly results. WHERE: Participants who wish to join the conference by telephone must register using the dial-in registration link below to receive the dial-in num...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: April 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financia...

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update – Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – – Matt Pulisic joined the company as its new Chief Financial Officer – – Closing of $10.5 Million Underwritten Offering of Common Stock – – $30.9 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif....

 PRESS RELEASE

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Of...

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. Titan Partners G...

 PRESS RELEASE

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of ...

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer –  Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant achieving a tumor reduction of approximately 79%. –  Additionally, three participants, including one individual with three prior lines of treatment, achieved stable disease at lower dose cohorts, with tumor size reductions ra...

 PRESS RELEASE

Genelux Announces Alignment with FDA on Key Elements of the Approval P...

Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease - U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval - WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Genelux has concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) for Olvi-Vec in the treatment of platinum resistant/r...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Macerich and PenFed Credit Union Secure Exclusive Sponsorship Agreemen...

Macerich and PenFed Credit Union Secure Exclusive Sponsorship Agreement for Tysons Corner Center Plaza Agreement Underscores PenFed Credit Union’s Long-Standing Commitment to the Local Community and its Members TYSONS, Va., March 20, 2025 (GLOBE NEWSWIRE) -- (NYSE: MAC), a leading owner, operator, and developer of major retail properties in top markets, has finalized terms with , America's second-largest federal credit union, on a new multi-year sponsorship and member engagement agreement. This exclusive deal enhances the branding power and reach of Tysons Corner Center’s experient...

Macerich Co: 1 director

A director at Macerich Co bought 7,000 shares at 16.400USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch